title: Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531).
authors: Vinod A
authors: VA
authors: Pullarkat
authors: Terry B
authors: TB
authors: Gernsheimer
authors: Jeffrey S
authors: JS
authors: Wasser
authors: Adrian
authors: A
authors: Newland
authors: Troy H
authors: TH
authors: Guthrie
authors: Joost Th M
authors: JT
authors: de Wolf
authors: Ron
authors: R
authors: Stewart
authors: Dietmar
authors: D
authors: Berger
mesh_terms: D002352:Carrier Proteins / Q000008:administration & dosage*; D002908:Chronic Disease; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage*; D008297:Male; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011961:Receptors, Fc / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin
chemical_list: D002352:Carrier Proteins; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim